Hanmi Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company specializing in the research, development, and commercialization of innovative drugs. The company focuses on therapeutic areas including metabolic disorders like diabetes and obesity, oncology, and other specialized fields. It has developed proprietary technologies for drug delivery and has a robust pipeline of candidates in clinical stages.
Headquartered in Seoul, South Korea, Hanmi operates primarily within the domestic market but extends its reach through global licensing partnerships with major pharmaceutical companies such as Merck. These collaborations allow for the development and potential commercialization of its compounds worldwide. The company is publicly listed on the Korea Exchange and maintains a strong emphasis on research and development, investing significantly in new drug discovery.
Hanmi Pharmaceutical positions itself as an innovative player in the Asian pharmaceutical industry, known for its ability to create value through out-licensing deals and its commitment to advancing healthcare solutions. It also engages in the production and marketing of both branded and generic pharmaceuticals, contributing to its diversified business model.
Also known as 한미약품 and Hanmi Pharm.
None yet. When a new project in the record names Hanmi Pharmaceutical as owner, partner or investor, it shows here.
Efinopegdutide achieved higher rates of MASH resolution and meaningful fibrosis improvement versus placebo at 52 weeks, with a safety profile broadly similar to semaglutide.
